2BBBullish & Bearish
Health Care

Emergent BioSolutions Inc. Common Stock (EBS) Stock Score & Signals

Emergent BioSolutions Inc. Common Stock (EBS) trades on NYSE. It operates in the Health Care sector, Drug Manufacturers - Specialty & Generic industry. Its current 2BB score is 49 out of 100.

About Emergent BioSolutions Inc. Common Stock

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.

2BB score and signals

Emergent BioSolutions Inc. Common Stock’s current 2BB score is 49 out of 100, built from the signal categories below.

SignalScoreReading
Activity52Moderate
Momentum45Stable
Financial strength52Normal
Quality100Very Strong
Risk47Moderate

Company facts

CEORobert G. Kramer Sr. | Joseph C. Papa
HeadquartersRockville, Maryland, United States
FoundedSep 5, 1998
Employees900
52-week range$4.36 – $14.06

Recent earnings

Report dateEPS actualEPS estimateRevenue actualRevenue estimate
2027-02-24-0.0808$145.10M
2026-10-27-0.3939$124.43M
2026-08-050.1111$179.28M
2026-04-300.21-0.2525$156.10M$146.45M